Clinical and immunological improvement in a patient with chronic mucocutaneous candidiasis treated with transfer factor.

Abstract

In a 19 year old patient suffering from CMC since the first months of life, clinical improvement accompanied by correction of the immunologic defect was achieved by Transfer Factor therapy. After 12 months from the last administration of Transfer Factor the improvement persisted. The positive outcome of the treatment in this disease is not constant. Possibly only patients with cellular immunologic defects are susceptible of a favourable response, moreover it is thinkable that the quality of Transfer Factor and the dosage administered must play a role.

• Authors: L Businco, F Aiuti, F Franchi, C Frati, R Cavalieri, E Rezza
• Journal: Allergologia et immunopathologia (Allergol Immunopathol (Madr)) 1976 Sep-Oct Vol. 4 Issue 5 Pg. 345-50 ISSN: 0301-0546 [Print] Singapore
• PMID: 1087530 (Publication Type: Case Reports, Journal Article)

Chemical References

• Transfer Factor
• Flucytosine

Topics

• Adult
• Candidiasis, Cutaneous (drug therapy, immunology)
• Chronic Disease
• Drug Therapy, Combination
• Evaluation Studies as Topic
• Female
• Flucytosine (therapeutic use)
• Humans
• T-Lymphocytes (immunology)
• Transfer Factor (immunology, therapeutic use)